Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0VZLQX)
| ADC Name |
BNT329
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
BNT329
Click to Show/Hide
|
|||||
| Organization |
BioNTech (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-CA19-9 antibody
|
Antibody Info | ||||
| Antigen Name |
CA19-9
|
Antigen Info | ||||
| Payload Name |
YL0010014
|
Payload Info | ||||
| Payload Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
VK*G-NHCH2-O linker
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
pelitecan
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Indication | Phase 1 | Phase 2 | Phase 3 | Approved | ||
|---|---|---|---|---|---|---|
| Gastroesophageal junction adenocarcinoma |
1 Trials
|
|||||
| Colorectal cancer |
1 Trials
|
|||||
| Pancreatic cancer |
1 Trials
|
|||||
| Biliary tract cancer |
1 Trials
|
|||||
| Ovarian cancer |
1 Trials
|
|||||
| Endometrial cancer |
1 Trials
|
|||||
| Urothelial cancer |
1 Trials
|